MedTrace Logo

The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis

NCT04684823 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-01-04

No results posted yet for this study

Summary

This proposed pilot study will assess if the Patch Technology system will increase adherence in patients with cystic fibrosis followed at the UTHSCSA Cystic Fibrosis Center.

Conditions

Interventions

DEVICE

Patch Cap

A prescription container cap to track the dispensing of an oral dose of medication with an associated app which tracks the adherence to medication regimen.

DEVICE

Patch App

A mobile app that is used with Patch Cap to track adherence to medication regimen

Sponsors & Collaborators

  • Patch Rx Technologies

    collaborator UNKNOWN

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Donna Beth J Willey-Courand, MD · UT Health San Antonio

  • Sarah J Kubes, Pharm D · UT Health San Antonio

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2021-12-27
Completion
2021-12-27
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04684823 on ClinicalTrials.gov